Connexion
M'inscrire

Votre recherche

Filtres

Project précédent
Projet suivant

20-0502

Mitochondrial-targeted antioxidant supplementation for improving age-related vascular dysfunction in humans
Source : Importé depuis le centre

Référence clinicaltrials.gov: NCT04851288
Aging
Recrutement ouvert
Dernière modification : 2024/02/16
Type de recherche

Interventionnel

Médicament expérimental

Phase 2


Population cible

Condition médicale (spécialité visée)

Choix aire thérapeutique

Aging

Source : Importé depuis le centre

Profil des participants

Sexe(s) des participants

All

Source : Importé depuis le centre

Critères de sélection

Critères d'inclusion

Inclusion Criteria:

Age 60 years and over
Ability to provide informed consent
Willing to accept random assignment to condition
Body mass index <40 kg/m2
Weight stable in the prior 3 months (<2 kg weight change) and willing to remain weight stable throughout the study
Free from alcohol dependence or abuse,
Mini-mental stage examination score ≥21

Exclusion Criteria:

Uncontrolled thyroid disease
Regular vigorous aerobic (>6 bouts/week, >60 min/bout at a workload >6 METS)
Blood donation within 8 weeks prior to enrolling in the study

Source : Importé depuis le centre

Thérapie ou Intervention proposée

Cohortes
Nom Condition médicale Traitement État du recrutement
MitoQ, 20 mg/day Donnée non disponible Each MitoQ capsule contains 20 mg of mitoquinol mesylate. Dosage: 20 mg orally per day for 3 months.
  • Inconnu
  • Placebo Donnée non disponible Matched placebo capsules.
  • Inconnu
  • MitoQ, 20 mg/day
    État du recrutement
    unknown
    Placebo
    État du recrutement
    unknown
    Données à jour depuis : 16 février 2024

    Description de l'étude

    Résumé de l'étude

    The majority of cardiovascular diseases (CVD) occur in men and women ≥60 years of age. Vascular dysfunction, including endothelial dysfunction, as assessed by reduced endothelium-dependent dilation (EDD), and stiffening of the large elastic arteries (i.e., aortic and carotid artery stiffening), is a major mechanism of increased risk of CVD in older adults. Excess production of ROS (reactive oxygen species) by mitochondria (mtROS) has emerged as a central feature of vascular oxidative stress with aging and driver of age-related vascular dysfunction. As such, identifying novel strategies to decrease mtROS and improve vascular function, to ultimately reduce the risk of age-related CVD, is an important biomedical objective.

    MitoQ is a mitochondria-targeted antioxidant that accumulates at the inner mitochondrial membrane where it is optimally positioned to reduce mtROS. Preclinical findings showed that 4 weeks of oral MitoQ supplementation completely restored EDD in old mice, ameliorated mtROS-associated suppression of EDD, and was associated with reduced arterial mtROS, oxidative stress, and improved mitochondrial health. MitoQ therapy also reduced aortic stiffness in old mice. A recent small pilot study of older adults (n=20) found that supplementation with MitoQ was well-tolerated, improved endothelial function, and reduced plasma levels of oxidized low-density lipoprotein, a circulating biomarker of oxidative stress. Consistent with the preclinical findings, preliminary mechanistic assessments in subsets of subjects from the pilot study suggested that improved endothelial function with MitoQ was mediated by reduced endothelial cell mtROS production, associated reductions in tonic mtROS-related suppression of EDD, and improved mitochondrial health, linked in part to changes in circulating factors in the serum induced by chronic MitoQ supplementation. Lastly, MitoQ reduced aortic stiffness in older adults who exhibited age-related aortic stiffening at baseline.

    The investigators are conducting a randomized, placebo-controlled, double-blind clinical trial to establish oral MitoQ (20 mg/day; MitoQ, Ltd.) for 3 months vs. placebo (n=56/group) for improving endothelial function in older men and women (≥60 years), and determine the mechanisms by which MitoQ improves endothelial function. The investigators will also assess the effect of MitoQ on aortic stiffness.

    Source : Importé depuis le centre

    Sites

    Centres participants

      1 centres
    • UNIVERSITY OF COLORADO BOULDER

      Boulder

      COLORADO, UNITED STATES

      Recrutement local
      État du recrutement: OUVERT
      Coordonnées pour le recrutement
      Contacts locaux
      chercheurs:

    Dernière modification : 16 février 2024
    Données à jour depuis : 22 mars
    Origine des données : clinicaltrials.gov
    Référence clinicaltrials.gov: NCT04851288